Satellos (NASDAQ: MSLE) sets virtual KOL event on SAT-3247 DMD program
Rhea-AI Filing Summary
Satellos Bioscience Inc. is organizing a virtual key opinion leader event on February 24, 2026 at 3:30 p.m. ET to discuss its lead drug candidate SAT-3247 for Duchenne muscular dystrophy (DMD). Neuromuscular disease expert Dr. Kevin M. Flanigan will review the unmet need and current DMD treatment landscape alongside company management.
The event will cover SAT-3247’s mechanism as an oral small molecule targeting AAK1 to help restore muscle stem-cell signaling disrupted by loss of dystrophin in DMD. It will highlight results from a completed Phase 1a/b trial in healthy volunteers and adults with DMD and provide updates on ongoing Phase 2 studies, including the adult open-label TRAILHEAD study and the global randomized, placebo-controlled pediatric BASECAMP trial.
Positive
- None.
Negative
- None.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
OF THE SECURITIES EXCHANGE ACT OF 1934
For the month of February 2026
(Commission File No. 001-43107)
SATELLOS BIOSCIENCE INC.
(Translation of registrant’s name into English)
Royal Bank Plaza, South Tower, 200 Bay Street, Suite 2800
Toronto, Ontario, ON M5J 2J3
(Address of registrant’s principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.
Form 20-F ¨ Form 40-F x
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101 (b) (1): ¨
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101 (b) (7): ¨
DOCUMENTS INCLUDED AS PART OF THIS FORM 6-K
| Exhibit | Description | |
| 99.1 | News release dated February 18, 2026. Satellos to Host Virtual KOL Event on SAT-3247 in Duchenne Muscular Dystrophy. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| Satellos Bioscience Inc. |
| By: | /s/ Elizabeth Williams, CPA, CA | |
| Name: | Elizabeth Williams, CPA, CA | |
| Title: | Chief Financial Officer |
Date: February 18, 2026
Exhibit 99.1
Satellos to Host Virtual KOL Event on SAT-3247 in Duchenne Muscular Dystrophy
TORONTO--(BUSINESS WIRE) — Satellos Bioscience Inc. (NASDAQ: MSLE, TSX: MSCL) (“Satellos” or the “Company”), a clinical-stage biotechnology company developing life-improving medicines to treat degenerative muscle diseases, today announced that it will host a virtual key opinion leader (KOL) event on Tuesday, Feb. 24, 2026, at 3:30 p.m. ET, featuring Kevin M. Flanigan, MD, the Wolfe Foundation Endowed Chair in Neuromuscular Research at Nationwide Children’s Hospital and professor of pediatrics and neurology at The Ohio State University College of Medicine. Dr. Flanigan will join company management to discuss the unmet need and current treatment landscape for Duchenne muscular dystrophy (DMD). Interested participants may register here.
The event will provide an overview of Satellos' SAT-3247, an oral small molecule therapy designed to restore natural muscle repair and regeneration in DMD and related conditions. SAT-3247 targets AAK1, a protein involved in muscle stem-cell signaling, a process that is disrupted in DMD due to the absence of dystrophin. The session will review results from the completed Phase 1a/b clinical trial in healthy volunteers and adults with DMD; outline TRAILHEAD, an open-label study in adult participants; and share updates on BASECAMP, an ongoing Phase 2 pediatric study.
ABOUT KEVIN M. FLANIGAN, MD
Kevin M. Flanigan, MD, is the Director of the Center for Gene Therapy at the Abigail Wexner Research Institute of Nationwide Children’s Hospital (NCH), where he holds the Robert F. & Edgar T. Wolfe Foundation Endowed Chair in Neuromuscular Research. Dr. Flanigan trained in Neurology and Neuromuscular Disease at the Johns Hopkins Hospital, followed by a post-doctoral fellowship in Human Molecular Biology and Genetics at the University of Utah. After 14 years on the faculty in Utah, he joined NCH in 2009. He is currently the director of the NCH P50-funded Wellstone Muscular Dystrophy Specialized Research Center and is a Professor of Pediatrics and Neurology at Ohio State University. His laboratory work is directed toward the identification of genetic modifiers of disease severity in the dystrophinopathies, and toward the molecular characterization and treatment of neuromuscular diseases, using both gene replacement and RNA-modifying therapies. His lab has a particular interest in AAV-delivered U7snRNAs modified to target specific exons in the DMD gene, which has led to a first-in-human clinical trial. He is an experienced clinical trialist and has conducted multiple clinical trials of gene transfer therapies in DMD, as well as the childhood neurodegenerative disorders mucopolysaccharidosis types 3A and 3B
ABOUT SAT-3247
SAT-3247 is a proprietary, oral, small molecule drug candidate being developed by Satellos as a novel approach to regenerating skeletal muscle lost in Duchenne muscular dystrophy (DMD) and other degenerative muscle diseases or injury conditions. Satellos is advancing SAT-3247 as a potential treatment for DMD that is independent of dystrophin and applicable regardless of exon mutation status, with ongoing Phase 2 clinical studies, including TRAILHEAD, an open-label study in adult participants, and BASECAMP, a global, randomized, placebo-controlled study in pediatric participants.
ABOUT SATELLOS BIOSCIENCE INC.
Satellos is a clinical-stage drug development company focused on restoring natural muscle repair and regeneration in degenerative muscle diseases. Through its research, Satellos has developed SAT-3247, a first-of-its-kind, orally administered small molecule drug designed to address deficits in muscle repair and regeneration. SAT-3247 targets AAK1, a key protein that Satellos has identified as capable of helping restore muscle stem-cell signaling, a process that is disrupted in DMD. By addressing the loss of dystrophin-dependent cues, SAT-3247 may re-establish the signals that support effective muscle regeneration. SAT-3247 is currently in clinical development as a potential disease-modifying treatment, initially for DMD. Satellos is also working to identify additional muscle diseases or injury conditions where restoring muscle repair and regeneration may have therapeutic benefit and represent future clinical development opportunities. For more information, visit www.satellos.com.
NOTICE ON FORWARD-LOOKING STATEMENTS
This press release includes forward-looking information or forward-looking statements within the meaning of applicable securities laws regarding Satellos and its business, which may include, but are not limited to, statements regarding the possibility of pursuing regulatory approval for SAT-3247, the potential for SAT-3247 to represent a disease modifying approach to the therapeutic treatment of people living with Duchenne; anticipated benefits to patients from a small molecule treatment for Duchenne; the advancement SAT-3247 through clinical trials, including the BASECAMP clinical trial; the pharmacodynamic properties and mechanism-of-action of SAT-3247; the potential of our approach in other degenerative muscle diseases; SAT-3247’s prospective impact on Duchenne patients, patients with other degenerative muscle disease or muscle injury or trauma, and on muscle regeneration generally; and Satellos’ technologies and drug development plans. All statements that are, or information which is, not historical facts, including without limitation, statements regarding future estimates, plans, programs, forecasts, projections, objectives, assumptions, expectations or beliefs of future performance, occurrences or developments, are “forward-looking information or statements.” Often, but not always, forward-looking information or statements can be identified by the use of words such as “shall”, “intends”, “believe”, “plan”, “expect”, “intend”, “estimate”, “anticipate”, “potential”, “prospective” , “assert” or any variations (including negative or plural variations) of such words and phrases, or state that certain actions, events or results “may”, “might”, “can”, “could”, “would” or “will” be taken, occur, lead to, result in, or, be achieved. Such statements are based on the current expectations and views of future events of the management of the Company. These statements are based on assumptions and subject to risks and uncertainties. Although management believes that the assumptions underlying these statements are reasonable, they may prove to be incorrect. The forward-looking events and circumstances discussed in this release, may not occur and could differ materially as a result of known and unknown risk factors and uncertainties affecting the Company, including, without limitation, risks relating to the pharmaceutical and bioscience industry (including the risks associated with preclinical and clinical trials and regulatory approvals), the research and development of therapeutics, the results of preclinical and clinical trials, general market conditions and equity markets, economic factors and management’s ability to manage and to operate the business of the Company generally, including inflation and the costs of operating a biopharma business, and those risks and uncertainties described in more detail in the “Risk Factors” section of Satellos’ Annual Information Form dated March 26, 2025 (which is located on Satellos’ profile at www.sedarplus.ca) and in Satellos’ public filings on SEDAR+ (sedarplus.ca) and EDGAR (sec.gov). Although Satellos has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events or results to differ from those anticipated, estimated or intended. Accordingly, readers should not place undue reliance on any forward-looking statements or information. No forward-looking statement can be guaranteed. Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made and Satellos does not undertake any obligation to publicly update or revise any forward-looking statement, whether resulting from new information, future events, or otherwise.
CONTACTS
Investors: Liz Williams, CFO, ir@satellos.com
Media: Emily Williams, Senior Director of Communications, media@satellos.com
FAQ
What did Satellos Bioscience (MSLE) announce in this Form 6-K?
When is Satellos’ virtual KOL event on SAT-3247 for Duchenne muscular dystrophy?
What is SAT-3247, Satellos Bioscience’s lead drug candidate for DMD?
Which clinical trials of SAT-3247 are currently ongoing according to Satellos?
Who is the key opinion leader speaking at Satellos’ DMD event?
How does SAT-3247’s mechanism of action relate to Duchenne muscular dystrophy?
Filing Exhibits & Attachments
1 documentPress Releases
